Alessandro Cicconi
Research Subjects
Alessandro Cicconi has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Eeson Rajendra
MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK
45 shared publications - Geoff S. Higgins
Department of Oncology, University of Oxford, Oxford, UK
45 shared publications - Gonzalo Rodriguez-Berriguete
Department of Oncology, University of Oxford, Oxford, UK
45 shared publications - Graeme C. M. Smith
Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
45 shared publications - Helen M. R. Robinson
Artios Pharma, Cambridge, UK
45 shared publications - Jayesh B. Majithiya
Artios Pharma, Cambridge, United Kingdom
45 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (24) , eaeb4508
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy
Inhibition of DNA polymerase theta (Polθ), an essential enzyme for repairing DNA double-strand breaks (DSBs) via microhomology-mediated end joining (MMEJ), has proven to be an exquisitely effective monotherapy in HR-deficient tumor models. In addition, Polθ inhibition (Polθi) can induce tumor-selective radiosensitization, but unlike its monotherapy use, no clinically actionable biomarkers have yet been identified to predict this effect. Here, we profiled 54 cancer cell lines and found that Polθi induces substantial radiosensitization in most models, although with marked variability not explained by indicators of Polθ activity. To pinpoint molecular determinants of radiosensitization by Polθi, we performed a CRISPR knockout screen which revealed loss of the TP53BP1/Shieldin pathway component SHLD2 ( FAM35A ) as a vulnerability to Polθi combined with RT. We found that SHLD2 is deleted in a subset of human prostate cancers, frequently alongside PTEN loss, an adverse prognostic factor. We demonstrated that SHLD2 loss not only increases sensitivity to RT alone, as reported previously, but also enhances the radiosensitizing effect of Polθi, independently of PTEN status and without requiring HR deficiency. Moreover, our findings support a model in which SHLD2 deficiency increases Polθ dependence following RT, with Polθ activity limiting DSB accumulation and chromosomal instability, via a compensatory mechanism independent of canonical MRE11/CtIP-mediated DNA end resection. In summary, we found that SHLD2 loss is a collateral vulnerability that can be exploited through combined treatment with Polθi and RT.
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (24) , eaeb4508
Open AccessSHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy
Inhibition of DNA polymerase theta (Polθ), an essential enzyme for repairing DNA double-strand breaks (DSBs) via microhomology-mediated end joining (MMEJ), has proven to be an exquisitely effective monotherapy in HR-deficient tumor models. In addition, Polθ inhibition (Polθi) can induce tumor-selective radiosensitization, but unlike its monotherapy use, no clinically actionable biomarkers have yet been identified to predict this effect. Here, we profiled 54 cancer cell lines and found that Polθi induces substantial radiosensitization in most models, although with marked variability not explained by indicators of Polθ activity. To pinpoint molecular determinants of radiosensitization by Polθi, we performed a CRISPR knockout screen which revealed loss of the TP53BP1/Shieldin pathway component SHLD2 ( FAM35A ) as a vulnerability to Polθi combined with RT. We found that SHLD2 is deleted in a subset of human prostate cancers, frequently alongside PTEN loss, an adverse prognostic factor. We demonstrated that SHLD2 loss not only increases sensitivity to RT alone, as reported previously, but also enhances the radiosensitizing effect of Polθi, independently of PTEN status and without requiring HR deficiency. Moreover, our findings support a model in which SHLD2 deficiency increases Polθ dependence following RT, with Polθ activity limiting DSB accumulation and chromosomal instability, via a compensatory mechanism independent of canonical MRE11/CtIP-mediated DNA end resection. In summary, we found that SHLD2 loss is a collateral vulnerability that can be exploited through combined treatment with Polθi and RT.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
ART558 treatment leads to increased residual IR-induced DNA damage foci. A, γH2AX and 53BP1 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed at the indicated times points after IR. B, Representative images from irradiated cells from the experiment described in A, at 16 hours after IR. C, Micronuclei in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 48 hours after IR. Data points indicate the mean ± SD from triplicate wells and graphs are representative from three separate experiments. D, Representative images from irradiated cells from the experiment described in C. Micronuclei are indicated with arrow heads. dsDNA, double-stranded DNA. E, RAD51 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 6 hours after IR. F, Representative images from irradiated cells from the experiment described in E. Lines and error bars in A and E correspond to average ± SD representative from three independent experiments, and statistical significance was calculated using nonparametric one-way ANOVA (Kruskal–Wallis) with Dunn correction for multiple comparisons (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
ART558 treatment leads to increased residual IR-induced DNA damage foci. A, γH2AX and 53BP1 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed at the indicated times points after IR. B, Representative images from irradiated cells from the experiment described in A, at 16 hours after IR. C, Micronuclei in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 48 hours after IR. Data points indicate the mean ± SD from triplicate wells and graphs are representative from three separate experiments. D, Representative images from irradiated cells from the experiment described in C. Micronuclei are indicated with arrow heads. dsDNA, double-stranded DNA. E, RAD51 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 6 hours after IR. F, Representative images from irradiated cells from the experiment described in E. Lines and error bars in A and E correspond to average ± SD representative from three independent experiments, and statistical significance was calculated using nonparametric one-way ANOVA (Kruskal–Wallis) with Dunn correction for multiple comparisons (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Cell cycle-dependent effects of ART558 in combination with IR
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Cell cycle-dependent effects of ART558 in combination with IR
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Distribution of POLQ mRNA levels across cell lines from CCLE
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Distribution of POLQ mRNA levels across cell lines from CCLE
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Accompanies Figure 4 (Characterization of ART899 as a specific and potent Polθ inhibitor with improved stability)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Accompanies Figure 4 (Characterization of ART899 as a specific and potent Polθ inhibitor with improved stability)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Polθ inhibitor ART899 combined with radiation causes significant tumor growth delay in vivo and is well tolerated. A, ART899 plasma concentration following oral dosage of ART899 at 50 or 150 mg/kg. Mouse plasma samples (n = 3 per treatment group) were collected at 30 minutes, 1, 2, 4, 8, and 12 hours after last dose. B–E, HCT116 tumor-bearing mice treated with 150 mg/kg Polθ inhibitor ART899 twice daily for 12 days and/or 10 × 2 Gy (days 1–5 and 8–12). Vehicle (n = 9); ART899 (n = 10); 10 × 2 Gy + vehicle (n = 10); 10 × 2 Gy + ART899 (n = 10). B, Mean ± SEM relative tumor size. P value from mixed effect model and Dunnett post-test. Comparison of tumor size at the latest common timepoint for 10 × 2 Gy versus 10 × 2 Gy + ART899 are shown in Supplementary Fig. S6A. C, Individual mouse graphs. D, Kaplan–Meier plot for a tumor size threshold of 1,000 mm3. HR: Hazard ratio (hazard rate of IR arm / hazard rate of IR + ART899 arm); P value from the log-rank (Mantel-Cox) test comparing IR alone and IR + ART558. The median time to a tumor size of 1,000 mm3 for the IR + ART899 arm versus the IR arm and the corresponding ratio are shown in Supplementary Fig. S6B. E, Average mouse weight ± SD from all treatment groups over time. Individual mouse weights are shown in Supplementary Fig. S6C.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Polθ inhibitor ART899 combined with radiation causes significant tumor growth delay in vivo and is well tolerated. A, ART899 plasma concentration following oral dosage of ART899 at 50 or 150 mg/kg. Mouse plasma samples (n = 3 per treatment group) were collected at 30 minutes, 1, 2, 4, 8, and 12 hours after last dose. B–E, HCT116 tumor-bearing mice treated with 150 mg/kg Polθ inhibitor ART899 twice daily for 12 days and/or 10 × 2 Gy (days 1–5 and 8–12). Vehicle (n = 9); ART899 (n = 10); 10 × 2 Gy + vehicle (n = 10); 10 × 2 Gy + ART899 (n = 10). B, Mean ± SEM relative tumor size. P value from mixed effect model and Dunnett post-test. Comparison of tumor size at the latest common timepoint for 10 × 2 Gy versus 10 × 2 Gy + ART899 are shown in Supplementary Fig. S6A. C, Individual mouse graphs. D, Kaplan–Meier plot for a tumor size threshold of 1,000 mm3. HR: Hazard ratio (hazard rate of IR arm / hazard rate of IR + ART899 arm); P value from the log-rank (Mantel-Cox) test comparing IR alone and IR + ART558. The median time to a tumor size of 1,000 mm3 for the IR + ART899 arm versus the IR arm and the corresponding ratio are shown in Supplementary Fig. S6B. E, Average mouse weight ± SD from all treatment groups over time. Individual mouse weights are shown in Supplementary Fig. S6C.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Accompanies Figure 5 (ART899 combined with radiation causes significant tumor growth delay in vivo and is well tolerated)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Accompanies Figure 5 (ART899 combined with radiation causes significant tumor growth delay in vivo and is well tolerated)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
ART558-mediated radiosensitization under hypoxic conditions. A, Clonogenic survival of H460 cells irradiated upon hypoxia (0.5% and <0.1% oxygen). For OERs, see Supplementary Fig. S4. The 6 Gy data points are replotted in a bar graph in B to allow better visual comparison between the different treatment arms (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
ART558-mediated radiosensitization under hypoxic conditions. A, Clonogenic survival of H460 cells irradiated upon hypoxia (0.5% and <0.1% oxygen). For OERs, see Supplementary Fig. S4. The 6 Gy data points are replotted in a bar graph in B to allow better visual comparison between the different treatment arms (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
The Polθ inhibitor ART558 radiosensitizes tumor cells. A and B, Clonogenic survival of HCT116, H460, and T24 cells treated with ART558 and/or IR. A, Plating efficiency for unirradiated cells. B, Surviving fractions as a function of the irradiation dose. Representative wells for 0 Gy and 6 Gy ± 1 μmol/L ART558 are shown for each cell line. C, Clonogenic survival of U2OS WT and Polθ KO cells treated with 3 μmol/L ART558 and 6 Gy IR. Bar graphs show the surviving fraction at 6 Gy. The Western blot insets confirm the lack of Polθ expression in the U2OS Polθ KO cells. D, Clonogenic survival of HCT116 and H460 cells transfected with either a control, nontargeting siRNA (siNT) or an siRNA targeted against POLQ (siPOLQ) and treated with 3 μmol/L ART558 and 6 Gy IR. Bar graphs show the surviving fraction at 6 Gy. Western blots show Polθ expression at the time of irradiation. E, Clonogenic survival of H460 and HCT116 treated with 3 μmol/L ART558 and 5×2 Gy (2 Gy once per day for 1 to 5 days). F and G, Clonogenic survival following irradiation and treatment with 3 μmol/L ART558 of synchronized HeLa cells. F, Representative histograms showing the cell-cycle distribution at the time of IR (synchronized in G1 by DT block or after 6 hours release from DT block, compared with asynchronous cultures). G, Degree of radiosensitization estimated by the ratio between the surviving fraction of DMSO- and ART558-treated cells after IR (SF DMSO / SF ART558). Data correspond to average ± SD from three independent experiments (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
The Polθ inhibitor ART558 radiosensitizes tumor cells. A and B, Clonogenic survival of HCT116, H460, and T24 cells treated with ART558 and/or IR. A, Plating efficiency for unirradiated cells. B, Surviving fractions as a function of the irradiation dose. Representative wells for 0 Gy and 6 Gy ± 1 μmol/L ART558 are shown for each cell line. C, Clonogenic survival of U2OS WT and Polθ KO cells treated with 3 μmol/L ART558 and 6 Gy IR. Bar graphs show the surviving fraction at 6 Gy. The Western blot insets confirm the lack of Polθ expression in the U2OS Polθ KO cells. D, Clonogenic survival of HCT116 and H460 cells transfected with either a control, nontargeting siRNA (siNT) or an siRNA targeted against POLQ (siPOLQ) and treated with 3 μmol/L ART558 and 6 Gy IR. Bar graphs show the surviving fraction at 6 Gy. Western blots show Polθ expression at the time of irradiation. E, Clonogenic survival of H460 and HCT116 treated with 3 μmol/L ART558 and 5×2 Gy (2 Gy once per day for 1 to 5 days). F and G, Clonogenic survival following irradiation and treatment with 3 μmol/L ART558 of synchronized HeLa cells. F, Representative histograms showing the cell-cycle distribution at the time of IR (synchronized in G1 by DT block or after 6 hours release from DT block, compared with asynchronous cultures). G, Degree of radiosensitization estimated by the ratio between the surviving fraction of DMSO- and ART558-treated cells after IR (SF DMSO / SF ART558). Data correspond to average ± SD from three independent experiments (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Characterization of ART899 as a specific and potent Polθ inhibitor with improved stability. A, Chemical structures of the Polθ inhibitors ART558 and ART899. The table shows the in vitro intrinsic clearance values of ART558 and ART899 after exposure to rat and mouse liver microsomes. B, Nano-luciferase MMEJ assay showing ART899-mediated inhibition of MMEJ activity in HEK-293 cells. The nano-luciferase readings were normalized to control luciferase (firefly) readings, and these were then normalized to DMSO. Data points show the mean ± SEM of four technical replicates; representative of two independent experiments. C, Confirmation of MMEJ assay specificity. Same experiment described in B but showing both the nanoluc and firefly readings normalized to their own DMSO reading, confirming negligible inhibition by ART899 of the control firefly luciferase signal. D, Clonogenic survival of HCT116 and H460 cells treated with ART899. Graphs show the surviving fraction after 5 × 2 Gy IR. E, Confirmation of ART899 specificity in U2OS WT and Polθ KO cells. Cells were treated as described in D. F, Effect of ART899 in noncancerous cells. MRC-5 and AG01552 fibroblasts were treated as described in D. The effect of ART899 in unirradiated cells from D to F is shown in Supplementary Fig. S5A. Graphs shown in D to F correspond to average ± SD from triplicate wells (representative from three separate experiments; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Viability of HIEC-6 cells treated with ART899 and irradiated with 5 × 2 Gy, as determined by the alamar blue assay 8 days after the first IR fraction. Graph shows the viability normalized to unirradiated controls (Supplementary Fig. S5C); representative from three independent experiments.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Characterization of ART899 as a specific and potent Polθ inhibitor with improved stability. A, Chemical structures of the Polθ inhibitors ART558 and ART899. The table shows the in vitro intrinsic clearance values of ART558 and ART899 after exposure to rat and mouse liver microsomes. B, Nano-luciferase MMEJ assay showing ART899-mediated inhibition of MMEJ activity in HEK-293 cells. The nano-luciferase readings were normalized to control luciferase (firefly) readings, and these were then normalized to DMSO. Data points show the mean ± SEM of four technical replicates; representative of two independent experiments. C, Confirmation of MMEJ assay specificity. Same experiment described in B but showing both the nanoluc and firefly readings normalized to their own DMSO reading, confirming negligible inhibition by ART899 of the control firefly luciferase signal. D, Clonogenic survival of HCT116 and H460 cells treated with ART899. Graphs show the surviving fraction after 5 × 2 Gy IR. E, Confirmation of ART899 specificity in U2OS WT and Polθ KO cells. Cells were treated as described in D. F, Effect of ART899 in noncancerous cells. MRC-5 and AG01552 fibroblasts were treated as described in D. The effect of ART899 in unirradiated cells from D to F is shown in Supplementary Fig. S5A. Graphs shown in D to F correspond to average ± SD from triplicate wells (representative from three separate experiments; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). G, Viability of HIEC-6 cells treated with ART899 and irradiated with 5 × 2 Gy, as determined by the alamar blue assay 8 days after the first IR fraction. Graph shows the viability normalized to unirradiated controls (Supplementary Fig. S5C); representative from three independent experiments.